Credit Suisse Ag Sage Therapeutics, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 103,406 shares of SAGE stock, worth $562,528. This represents 0.0% of its overall portfolio holdings.

Number of Shares

103,406

Previous 112,718 8.26%

Holding current value

$562,528

Previous $2.44 Million 20.68%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$18.62 - $26.95 $173,389 - $250,958	-9,312 Reduced 8.26%	103,406 $1.94 Million
Q4 2023 Feb 08, 2024	SELL	$17.1 - $22.26 $20,605 - $26,823	-1,205 Reduced 1.06%	112,718 $2.44 Million
Q3 2023 Nov 13, 2023	BUY	$16.75 - $48.98 $354,028 - $1.04 Million	21,136 Added 22.78%	113,923 $2.34 Million
Q2 2023 Aug 11, 2023	SELL	$40.65 - $59.54 $140,161 - $205,293	-3,448 Reduced 3.58%	92,787 $4.36 Million
Q1 2023 May 10, 2023	SELL	$37.27 - $46.57 $186,871 - $233,501	-5,014 Reduced 4.95%	96,235 $4.04 Million
Q4 2022 Feb 13, 2023	BUY	$32.2 - $43.61 $130,152 - $176,271	4,042 Added 4.16%	101,249 $3.86 Million
Q3 2022 Nov 10, 2022	BUY	$32.28 - $43.27 $6,165 - $8,264	191 Added 0.2%	97,207 $3.81 Million
Q2 2022 Aug 12, 2022	BUY	$27.52 - $37.99 $102,044 - $140,866	3,708 Added 3.97%	97,016 $3.13 Million
Q1 2022 May 16, 2022	BUY	$30.71 - $45.71 $379,606 - $565,021	12,361 Added 15.27%	93,308 $3.09 Million
Q4 2021 Feb 14, 2022	BUY	$37.06 - $47.11 $296,665 - $377,115	8,005 Added 10.97%	80,947 $3.44 Million
Q3 2021 Nov 12, 2021	BUY	$40.26 - $57.37 $58,618 - $83,530	1,456 Added 2.04%	72,942 $3.23 Million
Q2 2021 Aug 16, 2021	BUY	$54.88 - $79.29 $1.03 Million - $1.5 Million	18,855 Added 35.82%	71,486 $4.06 Million
Q1 2021 May 14, 2021	SELL	$70.65 - $96.76 $870,054 - $1.19 Million	-12,315 Reduced 18.96%	52,631 $3.94 Million
Q4 2020 Feb 12, 2021	SELL	$58.41 - $89.06 $309,748 - $472,285	-5,303 Reduced 7.55%	64,946 $5.62 Million
Q3 2020 Nov 13, 2020	SELL	$41.13 - $62.45 $1.85 Million - $2.8 Million	-44,859 Reduced 38.97%	70,249 $4.29 Million
Q2 2020 Aug 12, 2020	BUY	$25.95 - $43.15 $722,889 - $1.2 Million	27,857 Added 31.93%	115,108 $4.79 Million
Q1 2020 May 13, 2020	BUY	$26.15 - $77.24 $641,119 - $1.89 Million	24,517 Added 39.08%	87,251 $2.51 Million
Q4 2019 Feb 12, 2020	BUY	$60.18 - $154.77 $1.81 Million - $4.65 Million	30,042 Added 91.89%	62,734 $4.53 Million
Q3 2019 Nov 12, 2019	SELL	$140.29 - $189.96 $1.55 Million - $2.1 Million	-11,053 Reduced 25.27%	32,692 $4.59 Million
Q2 2019 Aug 14, 2019	BUY	$157.85 - $183.09 $2.35 Million - $2.72 Million	14,872 Added 51.51%	43,745 $8.01 Million
Q1 2019 May 14, 2019	SELL	$89.33 - $163.65 $7,593 - $13,910	-85 Reduced 0.29%	28,873 $4.59 Million
Q4 2018 Feb 13, 2019	SELL	$81.94 - $139.71 $307,356 - $524,052	-3,751 Reduced 11.47%	28,958 $2.77 Million
Q3 2018 Nov 13, 2018	SELL	$138.11 - $169.04 $265,033 - $324,387	-1,919 Reduced 5.54%	32,709 $4.62 Million
Q2 2018 Aug 14, 2018	SELL	$140.36 - $175.76 $2.49 Million - $3.12 Million	-17,772 Reduced 33.92%	34,628 $5.42 Million
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $1.6 Million - $2.02 Million	10,493 Added 25.04%	52,400 $8.44 Million
Q4 2017 Feb 14, 2018	SELL	$60.72 - $167.34 $2.19 Million - $6.04 Million	-36,070 Reduced 46.26%	41,907 $6.9 Million
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $898,282 - $1.3 Million	14,630 Added 23.1%	77,977 $4.86 Million
Q2 2017 Aug 14, 2017	BUY	N/A	63,347	63,347 $5.04 Million

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account